Immunovant
IMVT
112 hedge funds and large institutions have $219M invested in Immunovant in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 44 reducing their positions, and 19 closing their positions.
1,192% more call options, than puts
Call options by funds: $6.87M | Put options by funds: $532K
1.07% more ownership
Funds ownership: 32.91% → 33.98% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 118 → 112 (-6)
14% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 44
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
32% less capital invested
Capital invested by funds: $322M → $219M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$15.3M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.75M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$5.62M |
| 4 |
AGM
Alpine Global Management
New York
|
+$5.32M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.72M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
-$4.99M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.75M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.99M |
IMVT Hedge Fund Activity: Q1 2022 in Review
112 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2022, worth a combined $219M — down 32% from $322M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of IMVT and 13 opened new positions — a net loss of 6 holders — while 44 trimmed existing stakes and 38 added.
The largest buyer was Deep Track Capital, adding an estimated $15.3M. The largest seller was State Street, cutting an estimated $12.1M.
- 112 institutional investors held Immunovant (IMVT) as of Q1 2022, down from 118 in Q4 2021.
- Funds reported $219M of Immunovant stock for Q1 2022, down 32% quarter-over-quarter.
- 13 funds opened new Immunovant positions in Q1 2022 and 19 closed out, a net change of -6 holders.
- The largest Immunovant buyer in Q1 2022 was Deep Track Capital, an estimated $15.3M added.
- The largest Immunovant seller in Q1 2022 was State Street, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2022.